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ABSTRACT 102 
Objectives: To identify genetic determinants of susceptibility to clinical vertebral fractures, 103 
an important complication of osteoporosis. Methods: Here we conduct a genome-wide 104 
association study in 1,553 postmenopausal women with clinical vertebral fractures and 4,340 105 
controls, with a 2-stage replication involving 1,028 cases and 3,762 controls. Potentially 106 
causal variants were identified using eQTL data from transiliac bone biopsies and 107 
bioinformatic studies. Results: A locus tagged by rs10190845 was identified on chromosome 108 
2q13 which was significantly associated with clinical vertebral fracture (p=1.04x10
-9
) with a 109 
large effect size (odds ratio 1.74, 95% CI 1.06 – 2.6). Bioinformatic analysis of this locus 110 
identified several potentially functional SNPs which are associated with expression of the 111 
positional candidate genes TTL (Tubulin Tyrosine Ligase) and SLC20A1 (Solute Carrier 112 
Family 20 Member 1). Three other suggestive loci were identified on chromosomes 1p31, 113 
11q12 and 15q11. All these loci were novel and had not previously been associated with 114 
BMD or clinical fractures. Conclusion: We have identified a novel genetic variant that is 115 
associated with clinical vertebral fractures by mechanisms that are independent of BMD. 116 
Further studies are now in progress to validate this association and evaluate the underlying 117 
mechanism.   118 
 119 
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 136 
1. INTRODUCTION 137 
Osteoporosis is a common disease with a strong genetic component. It is characterised by low 138 
bone mineral density (BMD), deterioration in the microstructural architecture of bone and an 139 
increased risk of fragility fractures. Vertebral fractures are an early and important 140 
complication of osteoporosis.[1] They are characterised by loss of height and deformity of the 141 
affected vertebrae and associated with increased risk of other fractures.[2] It has been 142 
estimated that between 8-30% of patients with radiological evidence of vertebral fractures (so 143 
called morphometric fractures) come to medical attention for reasons that are incompletely 144 
understood.[3,4] In contrast, other patients with vertebral fractures come to medical attention 145 
because of symptoms such as back pain, kyphosis, and height loss, and are defined as having 146 
clinical vertebral fractures.[5-7]  Clinical vertebral fractures are associated with a markedly 147 
increased risk of future fractures and increased mortality.[8] Major advances have been made 148 
in identifying genetic variants that regulate BMD and some variants have also been identified 149 
that predispose to non-vertebral fractures.[9-20]  However, the genetic determinants of 150 
vertebral fractures are poorly understood. A previous genome-wide association study 151 
(GWAS) published by Oei and colleagues involving a discovery cohort of 8,717 cases and 152 
21,793 controls failed to identify any significant genetic predictors of radiographic vertebral 153 
fracture at a genome-wide significant level.[21] However, in this study, the vertebral 154 
fractures were defined simply on the basis of morphometric analysis of spinal radiographs. It 155 
is well recognised however that the morphometric techniques employed in this study may 156 
have identified vertebral deformities that were not fractures.[22] The aim of the present study 157 
was to re-evaluate the predictors of clinical vertebral fractures by genome wide association 158 
study to try and gain new insights into this important and poorly understood clinical problem.  159 
 160 
2. PATIENTS AND METHODS 161 
The study involved a discovery phase with 1,553 clinical vertebral fracture cases and 4,340 162 
controls, a first replication phase of 694 cases and 2,105 controls, and a second replication 163 
phase of 334 cases and 1,657 controls, as summarised in Supplementary Table 1. The 164 
genome wide association study was performed using standard methodology as detailed in the 165 
Supplementary Text 1.  166 
 167 
3. RESULTS 168 
3.1. Characteristics of the study populations 169 
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The mean (±standard deviation) age of the patients with clinical vertebral fractures was 170 
71.3±9.3 years with a bone mineral density T-score at the lumbar spine of -2.72±1.4; and at 171 
the femoral neck of -2.57±1.1. The controls were not matched with the cases by age and did 172 
not undergo phenotyping for vertebral fracture on the basis that clinical vertebral fractures are 173 
uncommon in the general population (estimated incidence of 9.8/1000 person-years in 75-84 174 
year olds)[23]. While it is possible that clinical vertebral fractures may have occurred in some 175 
controls in later life this is unlikely to have substantially affected the results of the analysis, 176 
other than to have potentially slightly reduced its power.[24] This approach has been used 177 
previously for genome-wide studies in various common diseases including diabetes, Paget’s 178 
disease, and rheumatoid arthritis.[25,26] 179 
We identified 334 clinical vertebral fracture female cases from the UK Biobank cohort with a 180 
mean age (±standard deviation) of 58.8±7.7 years, and they were age-matched with 1,657 181 
female controls from the same cohort.  182 
3.2. Genome-wide association analysis of the discovery sample 183 
Since different genotyping platforms were used in the analysis of the different cohorts that 184 
constitute the discovery sample, association analysis was conducted following imputation of 185 
all genotypes into the CEU panel of HapMap II reference (see Patients and Methods section). 186 
Following imputation, we analysed 2,366,456 SNPs and identified 31 with suggestive 187 
evidence of association with vertebral fracture (p<10
-4
). Details are summarised in 188 
Supplementary Table 2, the Manhattan and quantile-quantile plots are shown in 189 
Supplementary Figures 2 and 3. Each study was corrected by genomic control; genomic 190 
inflation factors ranged between =1.001 to =1.046 for genotyped SNPs and =1.006 to 191 
=1.036 after imputation. 192 
3.3. Replication and combined analysis 193 
We analysed the 31 suggestively associated SNPs identified in the discovery cohort 194 
(Supplementary Table 4) and seven additional SNPs that had been significantly associated 195 
with clinical fractures in a previous GWAS (Supplementary Table 5) in the replication 196 
sample.[10] Four SNPs showed nominal association (p<0.05) with clinical vertebral fractures 197 
at replication (Table 1). The combined discovery and replication analysis corrected for age 198 
identified one SNP (rs10190845) on chromosome 2q13 with genome-wide significant 199 
evidence of association with clinical vertebral fractures (p=1.27x10
-8
). The predisposing 200 
allele had a frequency of 0.034 in cases compared with 0.022 in controls and the odds ratio 201 
for susceptibility to fracture was 1.75 [95% CI: 1.44-2.12] (Figure 1). The results were 202 
similar without age correction (p=4.9x10
-8
; odds ratio 1.66 [95% CI: 1.38-1.99]). Conditional 203 
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analysis on rs10190845 did not reveal any secondary association signals at the locus 204 
(Supplementary Figure 4). Three other SNPs on chromosomes 1p31, 11q12 and 15q11 were 205 
suggestively associated with vertebral fracture in the combined analysis (Table 1 and 206 
Supplementary Figures 5 and 6). None of these regions have previously been found to be 207 
associated with BMD or fracture in previous GWAS.[10,13]  208 
The top SNP (rs10190845) maps to a region which contains eleven potential candidate genes 209 
(Figure 2). This region has previously been implicated as a genetic regulator of bone density 210 
by Estrada and colleagues[10] who reported that rs17040773 within ANAPC1 (Anaphase 211 
Promoting Complex Subunit 1) was associated with femoral neck BMD (p=1.5x10
-9
), but not 212 
with clinical fractures (p=0.79). rs17040773 is not in linkage disequilibrium with rs10190845 213 
in our population (r
2
=0.006), and, in keeping with this, when we performed conditional 214 
analysis on rs17040773, we confirmed that rs10190845 remained significantly associated 215 
with clinical vertebral fractures (p=2.09x10
-8
; odds ratio 1.73 [95% CI: 1.43-2.09]). In order 216 
to test whether the variants associated with clinical vertebral fractures played a role in BMD, 217 
we tested the rs10190845 variant for association with volumetric vertebral bone mineral 218 
density in females on the dataset from Nielson and colleagues.[27] We did not find any 219 
association for the variant and BMD (p=0.23). This suggests that rs10190845 constitutes an 220 
independent signal which predisposes to clinical vertebral fracture by mechanisms that are 221 
independent of an effect on BMD. 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
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Table 1. Variants showing suggestive or significant association with vertebral fracture  238 
    
Discovery 
(n = 5,893) 
Replication 
(n= 2,799) 
Combined* 
(n= 8,692) 
UK Biobank replication 
(n= 1,991) 
Total** 
(n= 10,683) 
Chr SNP Position A AF p 
OR 
(95% 
CI) 
AF p 
OR 
(95% 
CI) 
p 
OR  
(95% 
CI) 
I2 Q p AF p 
OR 
(95% 
CI) 
p 
OR 
(95% 
CI) 
I2 Q p 
2 rs10190845 112192944 A 0.03 2.4x10-5 
1.70 
(1.33-
2.17) 
0.05 1.60x10-4 
1.84 
(1.34-
2.53) 
1.27x10-8 
1.75 
(1.45-
2.12) 
5.9 0.39 0.05 0.027 
1.66 
(1.06-
2.60) 
1.04x10-9 
1.75 
(1.45-
2.12) 
0.0 0.48 
11 rs7121756 57980425 A 0.29 5.2x10-5 
1.22 
(1.11-
1.35) 
0.28 0.011 
1.23 
(1.05-
1.45) 
1.27x10-6 
1.23 
(1.13-
1.33) 
0.0 0.67 0.29 0.35 
1.09 
(0.91-
1.32) 
4.39x10-7 
1.22 
(1.13-
1.32) 
49.0 0.03 
15 rs2290492 92464744 A 0.23 3.4x10-5 
1.24 
(1.12-
1.37) 
0.21 0.021 
1.23 
(1.03-
1.46) 
1.61x10-6 
1.24 
(1.13-
1.35) 
53.7 0.02 0.22 0.44 
1.08 
(0.88-
1.33) 
2.51x10-7 
1.23 
(1.13-
1.33) 
75.6 1.1x10-5 
1 rs1360181 68248452 C 0.16 8.4x10-5 
1.25 
(1.12-
1.41) 
0.17 0.008 
1.30 
(1.07-
1.56) 
1.87x10-6 
1.26 
(1.14-
1.41) 
7.7 0.57 0.17 0.38 
0.90 
(0.72-
1.14) 
1.09x10-5 
1.22 
(1.12-
1.33) 
32.2 0.57 
 239 
The allele (A) and allele frequency (AF) for each of the variants is shown along with the p value for association, odds ratio (OR) and 95% 240 
confidence interval (95% CI). Q p values correspond to Cochran’s Q p-values. The values shown are adjusted for age but similar results were 241 
obtained for unadjusted association tests. Position refers to Human Genome Assembly GRCh38.p11. 242 
*Combined results showed the meta-analysis for discovery and replication stage. 243 
**Total results showed the meta-analysis including the second replication in the UK Biobank cohort. 244 
 245 
 246 
 247 
 248 
 249 
 250 
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A second replication for the significant hit on chromosome 2 and suggestive SNPs on 251 
chromosomes 1, 11 and 15 was performed in 334 clinical vertebral fracture cases and 1,657 252 
controls from UK Biobank. The top hit (rs10190845) on chromosome 2 was found nominally 253 
associated with clinical vertebral fractures (p=0.027, OR=1.66[1.060-2.600], MAF=0.049). 254 
No association was found for the suggestive SNPs in this cohort (Table 1).   255 
Meta-analysis of the discovery and the two replication stages showed a combined p-value for 256 
rs10190845=1.04x10
-9
 (OR=1.74[1.06-2.6]) with no evidence of heterogeneity between 257 
cohorts (I
2
=0.0, p=0.48) (Table 1). 258 
The SNPs rs7121756 on chromosome 11 and rs2290492 on chromosome 15 showed 259 
significant heterogeneity among cohorts (Cochrane’s Q<0.05), and a random effect analysis 260 
was performed. rs7121756 remained suggestively associated with clinical vertebral fractures 261 
(p=1.01x10
-6
), whilst rs2290492 showed a marginal association (p=0.004). 262 
3.4.Functional evaluation of chromosome 2q13 locus 263 
This analysis focused on a linkage disequilibrium block of approximately 700kb surrounding 264 
the top hit rs10190845. We identified a total of 936 SNPs within the region which were 265 
analysed in the GWAS (n=376) or which were in linkage disequilibrium (r
2
 value of > 0.7) 266 
with rs10190845, or which showed suggestive association to clinical vertebral fractures 267 
(p<5x10
-3
). We imputed the genotypes for the SNPs within the region of interest using the 268 
1000 Genomes phase 3 panel as reference and tested the SNPs for association with clinical 269 
vertebral fractures. We removed 878 of the SNPs since they showed no association with 270 
clinical vertebral fractures in our dataset (p>0.05). The remaining 58 candidate SNPs were 271 
tested for association with the level of expression of genes within the candidate locus using a 272 
bone-derived gene expression dataset (eQTLs)[28] (Tables 2, 3 and Supplementary Figure 7). 273 
This resulted in the identification of nine SNPs which were eQTLs for genes within the 274 
region. In order to gain insight into the functional basis of the association at 2q13 we used 275 
SuRFR[29] which integrates functional annotation and prior biological knowledge to identify 276 
potentially causal genetic variants, to assess these 9 SNPs along with the top hit rs10190845 277 
(Table 2 and Supplementary Figure 7).278 
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Table 2. Functionality of SNPs in 2q13 region, ranked by SuRFR 279 
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1 rs35586251 0.17 A (0.02) 2.09x10
-4
 
1.69 
(1.28-2.24) 
Exon FBLN7 4.47 0 0 7 5 0.02 0 0 9.89 Yes TTL 6.6 x 10
-6
 
2 rs77172864 0.79 G (0.03) 4.96x10
-5
 
1.68 
(1.31-2.17) 
Intergenic 0.18 0 0 1 3 0.02 0 0 8.56 Yes SCL20A1 0.0001 
3 rs10190845 1 A (0.03) 2.4x10
-5
 
1.70 
(1.33-2.17) 
Intergenic 0 0 0 2 3 0.96 0 0 8.06 No - - 
4 rs77996972 0.22 T (0.02) 2.11x10
-4
 
1.69 
(1.28-2.23) 
Intron FBLN7 1.77 313 0 7 1 0.02 0 0 7.61 Yes 
TTL 
SLC20A1 
3.8 x 10
-6 
5.5 x 10
-5
 
5 rs75814334 0.22 T (0.02) 2.11x10
-4
 
1.69 
(1.28-2.23) 
Intron FBLN7 0.43 239 0 8 1 0.02 0 0 7.56 Yes 
TTL 
SLC20A1 
2.1 x 10
-6 
6.6 x 10
-5
 
6 rs74792868 0.22 A (0.02) 2.1x10
-4
 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 9 1 0.02 0 0 7.5 Yes 
TTL 
SLC20A1 
2.0 x 10
-5 
2.8 x 10
-5
 
6 rs72943913 0.29 G (0.03) 5.48x10
-5
 
1.67 
(1.30-2.14) 
Intron ZC3H8 0.15 0 0 3 1 0.02 0 0 6.46 Yes SLC20A1 0.0001 
7 rs112275607 0.22 A (0.02) 2.13x10
-4
 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 8 1 0.02 0 0 6.83 Yes 
TTL 
SLC20A1 
2.8 x 10
-6 
6.2 x 10
-5
 
8 rs113085288 0.06 T (0.02) 1.79x10
-4
 
1.70 
(1.29-2.24) 
Intron FBLN7 0 0 0 7 1 0.02 0 0 6.08 Yes SLC20A1 4.1 x10
-6
 
9 rs113428223 0.29 T (0.03) 4.55x10
-5
 
1.70 
(1.31-2.20) 
Intron ZC3H6 0 0 0 2 1 0.02 0 0 5.61 Yes SCL20A1 0.0001 
A (AF): allele (allele frequency); GERP: Genomic evolutionary rate profiling; DNAase HS: DNase hypersensitivity; DNase foot: DNase 280 
footprint; Ernst score: classes of chromatin states (recurrent combinations of chromatin marks); MAF: minor allele frequency; TFBS: 281 
transcription factor binding site. Gene names: FBLN7: Fibulin 7; ZC3H8: Zinc Finger CCCH-Type Containing 8; ZC3H6: Zinc Finger CCCH-282 
Type Containing 6.  283 
 284 
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 285 
Table 3.  Correlation between genotypes for potentially functional SNP and bone-specific expression of genes in the candidate region  286 
 287 
RANK SNP GENE PROBE A1 A2 FRQ BETA SE P 
1 rs35586251 TTL 224896_s_at A G 0.017 0.65 0.13 6.62x10
-6
 
2 rs77172864 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
4 rs77996972 TTL 224896_s_at T C 0.012 0.67 0.13 3.80x10
-6
 
 
  SLC20A1 230494_at T C 0.012 -0.49 0.11 5.50x10
-5
 
5 rs75814334 TTL 224896_s_at T C 0.013 0.67 0.13 2.10x10
-6
 
 
  SLC20A1 230494_at T C 0.013 -0.48 0.11 6.60x10
-5
 
6 rs74792868 TTL 224896_s_at A G 0.012 0.66 0.14 2.00x10
-5
 
 
  SLC20A1 230494_at A G 0.012 -0.53 0.12 2.80x10
-5
 
6 rs72943913 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
7 rs112275607 TTL 224896_s_at A G 0.013 0.67 0.13 2.80x10
-6
 
 
  SLC20A1 230494_at A G 0.013 -0.48 0.11 6.02x10
-5
 
8 rs113085288 SLC20A1 230494_at T A 0.008 -0.72 0.14 4.06x10
-6
 
9 rs113428223 SLC20A1 230494_at T C 0.013 -0.46 0.11 0.0001 
 288 
The data shown are only for the associations which were significant after Bonferroni correction (p value for significance <0.0002).  A1: allele 1, 289 
A2: Allele 2, FRQ: frequency of allele 1, BETA: effect size on regression analysis referred to A1 allele, SE: standard error of beta estimate, 290 
probe IDs obtained from the Affymetrix HG U133 2.0 plus array. Gene names: TTL: Tubulin Tyrosine Ligase; SLC20A1: Solute Carrier Family 291 
20 Member 1 (also known as PIT1).  292 
 293 
13 
 
The top ranking variant identified by SuRFR, rs35586251, located within exon 3 of FBLN7 is 294 
a non-synonymous substitution (p.Val119Met). However, analysis using various in silico 295 
software tools yielded inconsistent results with regard to functionality of this SNP at the 296 
protein level (Supplementary Table 6). The other 9 SNPs are associated with expression of 297 
TTL, SCL20A or both genes. The variant that ranked top by SuRFR, rs35586251, was 298 
associated with increased expression of TTL (p=6.6x10
-6
). Four other variants were also 299 
associated with both increased expression of TTL and reduced expression of SLC20A1 (p-300 
values ranging from 2.1x10
-6
 to 10
-5
). The second ranking variant, rs77172864, in strong LD 301 
with the GWAS top hit (r
2
=0.79), was associated with reduced expression of SLC20A1 (p=10
-
302 
4
) (Tables 2 and 3).   303 
The variants listed on Table 2 were tested in the UK Biobank cohort for further association 304 
with clinical vertebral fractures (Supplementary Table 7). Although none of them was 305 
significantly associated with the trait, a trend of significance was found for SNPs 306 
rs72943913, rs77172864, and rs113428223 (p=0.06, OR=1.66), and all of them identified as 307 
eQTLs for SLC20A1 gene in bone. These variants showed a lower frequency (MAF=0.03) 308 
than the top hit (MAF=0.05), which could require a greater sample size to detect associations 309 
with the trait. 310 
3.5.  Association between clinical vertebral fractures and other osteoporosis related 311 
phenotypes 312 
In order to determine if there is overlap between the SNPs identified as associated with 313 
lumbar spine BMD in previous GWAS with those associated with clinical vertebral fracture 314 
in this study, we evaluated 50 SNPs that have been associated with lumbar spine BMD at a 315 
genome-wide significant level in previous studies in our dataset.[10,11,13,30,31] Four 316 
variants were nominally associated with clinical vertebral fracture after Bonferroni correction 317 
(Table 4). We also analysed 15 variants previously associated with clinical fracture,[13]  of 318 
which three were associated with clinical vertebral fractures in this study. We also analysed 319 
the SNPs identified by Nielson and colleagues[27] as genome-wide significant predictors of 320 
volumetric vertebral bone mineral density for association with clinical vertebral fractures in 321 
our dataset. Of the six genome-wide significant SNPs identified by Nielson et al, we found 322 
that one was significantly associated with clinical vertebral fractures after Bonferroni 323 
correction (rs12742784, p=6.24x10
-5
). The BMD-increasing variants in Table 4 conferred a 324 
reduced risk of clinical vertebral fractures in our study, whilst the variants associated with 325 
appearance of clinical fractures in previous studies were also associated with a higher risk of 326 
developing a clinical vertebral fracture in our data.  327 
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Table 4. Association between known genetic determinants of spine BMD and clinical vertebral fractures in the combined GWAS 329 
dataset. 330 
Previous studies Present study 
Study SNP Locus Candidate gene Phenotype Method Allele Beta
1
 p Beta
2
 p 
Estrada rs1346004 2q24.3 GALNT3 LS-BMD DXA A ‐0.06 3.87x10‐30 +0.16 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 LS-BMD DXA C +0.07 2.13x10‐
35
 -0.15 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 LS-BMD DXA C +0.1 1.86x10‐
44
 -0.22 0.0003 
Styrkarsdottir rs7524102 1p36 WNT4 LS-BMD DXA A -0.11 9.2x10
-9
 +0.23 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 Clinical fracture Clinical records 
and X-rays 
G +0.08 5.9x10
-11
 +0.14 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 Clinical fracture Clinical records 
and X-rays 
G +0.07 3.6x10
-6
* +0.22 0.0003 
Estrada rs6959212 7p14.1 STARD3NL Clinical fracture Clinical records 
and X-rays 
T +0.05 7.2x10
-5
* +0.15 0.001 
Nielson rs12742784 1p36.12 ZBTB40 Vertebral BMD qCT imaging T +0.09 1.05x10
-10
 -0.20 6.24x10
-5
 
 331 
The variants shown are those that were significant after Bonferroni correction for testing 56 BMD variants (p threshold for association 0.0009) 332 
and 16 fracture variants (p threshold for association 0.003). *SNP significantly associated with clinical fracture after Bonferroni correction (p 333 
threshold at Estrada et al 5x10
-4
). 334 
Beta
1
 showed the effect for the previous studies (LS-BMD, clinical fracture and vertebral BMD). 335 
Beta
2
 showed the effect for the present study on clinical vertebral fracture 336 
Gene names: GALNT3: Polypeptide N-Acetylgalactosaminyltransferase 3); SLC25A13: Solute Carrier Family 25 Member 13; ZBTB40: Zinc 337 
Finger And BTB Domain Containing 40; WNT4: Wnt Family Member 4; STARD3NL: StAR Related Lipid Transfer Domain Containing 3 N-338 
Terminal Like). 339 
Method column shows the technique used to evaluate the BMD or assess the fracture (DXA: dual energy X-ray absorptiometry, CT: quantitative 340 
computerised tomography) 341 
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4. DISCUSSION 342 
Many advances have been made in defining the genetic determinants of bone mineral density 343 
and fractures through large scale genome-wide association studies, genome sequencing 344 
studies and linkage studies in rare bone diseases.[32] For example, linkage studies have 345 
shown that loss-of-function and gain-of-function variants in LRP5 cause early onset 346 
osteoporosis[33] and high bone mass[34] respectively, whereas loss of function mutations 347 
affecting SOST and LRP4 have been identified as causes of high bone mass and 348 
osteosclerosis.[35,36] Genome-wide association studies and genome sequencing studies have 349 
also been successful in identifying multiple loci that regulate bone mineral density[9-350 
11,30,37] and a smaller number that predispose to clinical fractures.[10,30]  351 
Although vertebral fractures are one of the most common and important complications of 352 
osteoporosis, relatively little is known about the genetic determinants of this type of 353 
fracture.[38] In a previous study of 8,717 cases and 21,793 controls, Oei and colleagues 354 
failed to identify any locus with significant evidence of association with morphometric 355 
vertebral fractures.[21] In the present study however, we were successful in identifying one 356 
genome-wide significant variant that predisposed to clinical vertebral fractures, which was 357 
replicated in several populations. We also detected loci that might play a role in clinical 358 
vertebral fractures (showing suggestive association at the genome-wide level), but further 359 
studies need to be performed in further cohorts to confirm or refute these associations. A 360 
likely reason for the difference between our findings and those of Oei et al, is varying case 361 
definition. Here, we studied patients with clinical vertebral fractures as opposed to 362 
morphometric vertebral deformities, many of which may not be true fractures.[22] The 363 
genome-wide significant SNP identified in the present study, rs10190845, shows one of the 364 
largest effect size so far detected in the field of osteoporosis genetics (OR=1.75[1.45-2.12]). 365 
Most of the signals associated with BMD or fracture to date showed a very low effect (ORs 366 
between 0.90 and 1.10),[12,13] with a few exceptions.[20]  367 
rs10190845 maps to chromosome 2q13, a region previously associated with low femoral 368 
neck bone density.[10] However, when conditioning on rs17040773, the previously reported 369 
top SNP at the locus,[10] the association with rs10190845 remained significant, indicating 370 
that rs10190845 represents a novel signal. 371 
In order to determine if there was an overlap between the results of this study and those 372 
previously reported, we analysed 71 SNPs that have previously been associated with either 373 
spine BMD or clinical fractures and identified seven variants that were significantly 374 
associated with clinical vertebral fracture in this study, after Bonferroni correction (threshold 375 
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for significance 0.0009 for BMD and 0.003 for clinical fractures). However, the association 376 
for these variants did not reach genome-wide significance, therefore, they were not selected 377 
in the GWAS analysis. The SNPs associated with low BMD as well as increased risk of 378 
clinical fractures in previous studies were associated with an increased risk of clinical 379 
vertebral fractures in this study and those associated with an increased risk of clinical 380 
fractures in previous studies were associated with an increased risk of clinical vertebral 381 
fractures in this study.  382 
Furthermore, when we analysed six SNPs that were significantly associated with vertebral 383 
bone mineral density on quantitative computerised tomography (qCT) analysis[27] one locus 384 
on chromosome 1p36, close to ZBTB40, was identified and significantly associated with 385 
clinical vertebral fracture in this study. These results support the importance of ZBTB40 as a 386 
predictor of clinical fractures and suggest that the mechanism of association is most probably 387 
mediated by changes in BMD. The observations in this study, when taken together with the 388 
findings of Nielson and Estrada[10,27] indicate that there is a partial overlap between loci 389 
that regulate lumbar spine BMD, and clinical vertebral fractures. However, there are some 390 
genetic determinants of clinical vertebral fracture which are unique and which operate 391 
independently of BMD.  392 
In order to identify the mechanisms by which 2q13 predisposes to vertebral fracture we 393 
conducted bioinformatics analyses to determine if rs10190845 or other SNPs nearby were 394 
likely to be functional variants. These studies identified several potentially functional SNPs 395 
in the same LD block as rs10190845, which might account for the association we observed. 396 
The top ranking SNP from SuRFR analysis was rs35586251, which was strongly associated 397 
with expression of the TTL gene within the candidate locus (Supplementary Figure 8). 398 
However, the second ranking SNP, rs77172864 (Supplementary Figure 9), in strong LD with 399 
the GWAS top hit, was significantly associated with the expression of SLC20A1. Several 400 
other SNPs were also significantly associated with expression of TTL and/or SLC20A1, 401 
raising the possibility that alterations in expression of one or both genes might account for the 402 
predisposition to clinical vertebral fractures. Association analysis performed using UK 403 
Biobank cohort for these SNPs showed a trend of association for markers regulating 404 
SLC20A1 gene, which also showed some degree of linkage disequilibrium, with the GWAS 405 
top hit. The lack of significant association might be due to their low allele frequency 406 
(MAF=0.03), which means that a larger sample size may be required to detect a strong 407 
association. The Tubulin Tyrosine Ligase encoded by TTL is involved in regulation of the 408 
cytoskeleton. Previous studies have shown that TTL is involved in neuronal development[39] 409 
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and injury signalling,[40] raising the possibility that variants that regulate TTL might be 410 
involved in regulating pain perception, which could account for the fact that predisposing 411 
variants have not previously been associated with BMD. Other mechanisms might also be 412 
possible and further studies need to be performed in order to address the role of TTL in 413 
clinical vertebral fracture. The other main candidate gene, SLC20A1, encodes Pit1, which 414 
facilitates the entry of inorganic phosphate into the cytoplasm.[41] Previous studies have 415 
shown that SLC20A1 is involved in mineralisation.[42-45] Altered expression of this gene 416 
could convey risk for vertebral fractures via an effect on bone mineralisation. Although 417 
SLC20A1 presents as the candidate gene for association with clinical vertebral fractures in 418 
this study, it has not been identified previously as a predictor of BMD or fractures. This 419 
opens for alternative mechanisms, or that TTL rather than SLC20A1 is the candidate gene 420 
within the 2q13 locus.  421 
Limitations of the study include the fact that the total sample size was relatively small and the 422 
power to detect alleles of modest effect size was limited. It is possible that we may have 423 
missed associations between rare variants and clinical vertebral fractures since the imputation 424 
we performed was against HapMap reference panel rather than larger panels that increase 425 
imputation power particularly against low frequency variants. Although case definition was 426 
clinically based, there was no significant heterogeneity in the associations we observed across 427 
centres.   428 
Strengths of the present study are that it has provided important new information on the 429 
genetic determinants of clinical vertebral fracture and that results, despite the sample size, 430 
have been validated in two independent replication stages.  431 
4.1. Conclusion 432 
Genome wide association analysis identified a significant association between a marker on 433 
chromosome 2 and clinical vertebral fractures in postmenopausal women, a finding validated 434 
in several independent populations.  435 
It is of interest that the top hit and other suggestive hits identified acted independently of 436 
BMD, bringing to attention other bone microarchitectural modalities that determine fracture 437 
susceptibility. This suggests that the variants identified might be acting as markers for 438 
perception of pain or other factors that are associated with the clinical presentation of 439 
vertebral fractures. We also found that some of the variants previously identified as regulators 440 
of spine BMD were associated with clinical vertebral fractures, but with effects that were 441 
weaker than the top hit and other suggestive hits. Taken together, the data suggest that the 442 
genetic basis of clinical vertebral fracture is complex involving variants that act 443 
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independently of BMD as well as those that are associated with spine BMD. Further research 444 
is now warranted to fully investigate the mechanisms involved.  445 
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Fig 1. Cohort specific association between rs10190845 and clinical vertebral fracture 654 
The point estimates (squares) and 95% confidence intervals (horizontal lines) for individual 655 
studies are shown with the summary indicated by the diamond using a fixed effect model. 656 
Summaries are shown for meta-analysis with discovery cohorts only (Summary_discovery), 657 
with the first replication cohorts only (Summary_replication), and for the whole 3-stage 658 
meta-analysis (Summary_meta-analysis). “BRITISH-WTCCC” shows the results for the 659 
combined cohorts CAIFOS, AOGC, DOES, and EPIC, and the control cohort WTCCC2. 660 
“Scottish replication” corresponds to EDOS-ORCADES cohorts, “Italian_replication_1” 661 
study corresponds to Florence-InCHIANTI cohorts and “Italian_replication_2” study 662 
comprises the Turin and Siena cohorts. Cohort sizes are reflected by square dimensions. 663 
 664 
 665 
Fig 2. Regional association plots of susceptibility locus for clinical vertebral fracture 666 
The figure shows the results after imputation using 1000G v3 as reference panel. The SNPs 667 
are colour coded according to the extent of LD with the SNP showing the highest association 668 
signal from the combined analysis (represented as a purple diamond). The estimated 669 
recombination rates (cM/Mb) from HapMap CEU release 22 are shown as light blue lines, 670 
and the blue arrows represent known genes in the region. The red line shows the threshold for 671 
genome-wide significance (p = 5 x 10
-8
) 672 
